Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Status:
Completed
Trial end date:
2018-06-11
Target enrollment:
Participant gender:
Summary
This is an open-label phase III study of regorafenib in patients with metastatic colorectal
cancer (mCRC) who have progressed after all approved standard therapy. The purpose of this
study is to provide additional information about the safety profile of Regorafenib.